Citation Impact
Citing Papers
CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy
2013
Systematic Review of Pretreatment Prostate-Specific Antigen Velocity and Doubling Time As Predictors for Prostate Cancer
2008
Decision Curve Analysis: A Novel Method for Evaluating Prediction Models
2006 Standout
Hallmarks of Cancer: The Next Generation
2011 Standout
Major depressive disorder
2016 Standout
Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of 4–20 ng/ml
1997
Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases
1994
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
2018
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
2016 Standout
Myeloid-derived suppressor cells coming of age
2018 Standout
Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.
1997
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers
2005
Clinical utility of telomerase in cancer
2002
The attractive Achilles heel of germ cell tumours: an inherent sensitivity to apoptosis‐inducing stimuli
2003
Microsatellite Instability in Colorectal Cancer
2010 Standout
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
2016 Standout
Recent results of management of palpable clinically localized prostate cancer
1993
The management of PSA failure after radical radiotherapy for localized prostate cancer
1998
Derailed endocytosis: an emerging feature of cancer
2008
Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer
1997
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
2012 Standout
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
1999 Standout
Salvage brachytherapy for localized prostate cancer after radiotherapy failure
1999
Hyaluronan: from extracellular glue to pericellular cue
2004 Standout
Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer
1998 Standout
Noninvasive Detection of Clinically Occult Lymph-Node Metastases in Prostate Cancer
2003 Standout
Multiplexed electrical detection of cancer markers with nanowire sensor arrays
2005 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Coordinated regulation of myeloid cells by tumours
2012 Standout
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
Cancer Volume of Lymph Node Metastasis Predicts Progression in Prostate Cancer
1998
Prostate specific antigen: biology, biochemistry and available commercial assays
2001
Rab GTPases as coordinators of vesicle traffic
2009 Standout
Comparison of Conventional-Dose vs High-Dose Conformal Radiation Therapy in Clinically Localized Adenocarcinoma of the Prostate
2005 Standout
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
2005 Standout
The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma
2005 Standout
Testicular germ-cell tumours in a broader perspective
2005 Standout
A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate Cancer
1998
Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer
2009
EAU Guidelines on Prostate Cancer
2007 Standout
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews
2005 Standout
Prevention of Venous Thromboembolism
2004 Standout
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
2016 Standout
Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors
1992
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
2011 Standout
Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer
1998
Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy
1995
Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid–hyaluronidase and BTA‐Stat tests
2002
Oxidative Stress in Cancer
2020 Standout
Macrophages as regulators of tumour immunity and immunotherapy
2019 Standout
Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment
2004
Zygomycosis (mucormycosis): emerging clinical importance and new treatments
2004
Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer.
1993
Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms
2013 Standout
Prostate-specific antigen and radiation therapy for clinically localized prostate cancer
1995
Anatomic site-specific positive margins in organconfined prostate cancer and its impact on outcome after radical prostatectomy
1997
In vivo imaging of tumors with protease-activated near-infrared fluorescent probes
1999 Standout
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
2006 Standout
Neuropsychiatric disorders related to interferon and interleukins treatment
2008
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
2016 Standout
Prostatic Specific Antigen
1994
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers
2004
CCL2 is critical for immunosuppression to promote cancer metastasis
2012
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013
2013 Standout
Robotic radical prostatectomy: A technique to reduce pT2 positive margins
2004 StandoutNobel
Bladder neck incision using a 70 W 2 micron continuous wave laser (RevoLix)
2007
Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy
2006 Standout
NAD + /NADH and NADP + /NADPH in Cellular Functions and Cell Death: Regulation and Biological Consequences
2007 Standout
Emerging Role of RAB GTPases in Cancer and Human Disease
2005
Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens
2005
RECURRENCE PATTERNS AFTER RADICAL RETROPUBIC PROSTATECTOMY: CLINICAL USEFULNESS OF PROSTATE SPECIFIC ANTIGEN DOUBLING TIMES AND LOG SLOPE PROSTATE SPECIFIC ANTIGEN
1997
Influence of Capsular Penetration on Progression Following Radical Prostatectomy: A Study of 196 Cases with Long-Term Followup
1993
Role of Telomeres and Telomerase in the Pathogenesis of Human Cancer
2003
Towards high-power mid-infrared emission from a fibre laser
2012 Standout
Antitumor Activity of Systemically Delivered Ribozymes Targeting Murine Telomerase RNA
2004 StandoutNobel
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells
2011
Tumor Markers in the Diagnosis of Primary Bladder Cancer. A Systematic Review
2003
Genes and pathways downstream of telomerase in melanoma metastasis
2006 StandoutNobel
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Randomized, Prospective, Controlled Study Comparing Radical Prostatectomy Alone and Neoadjuvant Androgen Withdrawal in the Treatment of Localized Prostate Cancer
1996
The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
2016
Can Radical Prostatectomy Alter the Progression of Poorly Differentiated Prostate Cancer?
1994
PROSTATE SPECIFIC ANTIGEN ONLY PROGRESSION OF PROSTATE CANCER
2000
ATM Mediates Cytotoxicity of a Mutant Telomerase RNA in Human Cancer Cells
2008 StandoutNobel
RADICAL RETROPUBIC PROSTATECTOMY PLUS ORCHIECTOMY VERSUS ORCHIECTOMY ALONE FOR pTxN+ PROSTATE CANCER: A MATCHED COMPARISON
1999
BENIGN AND MALIGNANT NEOPLASMS OF PROSTATE
2000
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
2002 Standout
Patient Selection for Salvage Cryotherapy for Locally Recurrent Prostate Cancer After Radiation Therapy
1999
PREDICTIVE VALUE OF PROSTATE SPECIFIC ANTIGEN NADIR AFTER SALVAGE CRYOTHERAPY
1998
The Tumor Microenvironment Innately Modulates Cancer Progression
2019 Standout
The Incidence and Significance of Detectable Levels of Serum Prostate Specific Antigen After Radical Prostatectomy
1994
Pathologic and Clinical Findings to Predict Tumor Extent of Nonpalpable (Stage T1 c) Prostate Cancer
1994 Standout
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer
2007 StandoutNobel
Invasive disease due to Mucorales: a case report and review of the literature.
2001
Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years.
1993
Prostate Specific Antigen Based Disease Control Following Ultrasound Guided sup 125 Iodine Implantation for Stage T1/T2 Prostatic Carcinoma
1995
The Effect of Pelvic Radiation Therapy on Serum Levels of Prostate Specific Antigen
1994
Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group.
1996
Neoadjuvant Hormonal Therapy Before Radical Prostatectomy Decreases the Number of Positive Surgical Margins in Stage T2 Prostate Cancer: Interim Results of a Prospective Randomized Trial
1995
Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate Cancer
1995
Consensus statement: Guidelines for PSA following radiation therapy1
1997 Standout
Systematic reviews: CRD's guidance for undertaking reviews in health care
2010 Standout
Works of Avi Stein being referenced
Predominant Expression of CCL2 at the Tumor Site of Prostate Cancer Patients Directs a Selective Loss of Immunological Tolerance to CCL2 That Could Be Amplified in a Beneficial Manner
2009
Interleukin‐2, interferon‐α, 5‐fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma
2002
Molecular analysis of transitional cell carcinoma using cDNA microarray
2003
Urinary Cytokeratin 20 as a Marker for Transitional Cell Carcinoma
2000
Dissecting the Autocrine and Paracrine Roles of the CCR2-CCL2 Axis in Tumor Survival and Angiogenesis
2012
Salvage radical prostatectomy after failure of curative radiotherapy for adenocarcinoma of prostate
1992
The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity
1997
Hyperbaric Oxygen Therapy for Cutaneous/Soft-Tissue Zygomycosis Complicating Diabetes Mellitus
1998
Activated status of tumour‐infiltrating lymphocytes and apoptosis in testicular seminoma
2001
Prostatic Specific Antigen Related to Clinical Status 1 to 14 Years after Radical Retropubic Prostatectomy
1991
New Modality for Treatment of Resistant Anastomotic Strictures After Radical Prostatectomy: UroLume Urethral Stent
2001
Prognosis of Patients with Stage D1 Prostate Carcinoma Following Radical Prostatectomy with and Without Early Endocrine Therapy
1990
Hyperbaric Oxygen Therapy for Cutaneous/Soft-Tissue Zygomycosis Complicating Diabetes Mellitus
1998
TELOMERASE ACTIVITY AND CYTOKERATIN 20 AS MARKERS FOR THE DETECTION AND FOLLOWUP OF TRANSITIONAL CELL CARCINOMA: AN UNFULFILLED PROMISE
2001
Neoadjuvant Hormonal Deprivation in Patients with Locally Advanced Prostate Cancer
1993
Detection of Local Recurrence After Radical Prostatectomy by Prostate Specific Antigen and Transrectal Ultrasound
1992
Prostate Specific Antigen Levels After Radical Prostatectomy in Patients with Organ Confined and Locally Extensive Prostate Cancer
1992
Telomerase activity in patients with transitional cell carcinoma
1999